<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3a8/4826182/bda027522db3/oncotarget-07-3947-g006.jpg"/> </div> <div class="text-side"> <h1>Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.</h1> <p>Inhibition of p-ERK and p-AKT in-vivo by combinatorial treatments in a PLX4720-resistant cell lineImmunohistochemistry analysis by staining with anti-p-ERK (A) and anti-pAKT (B) antibodies of tumor nodules (images of nodules from two animals are shown for each signaling molecule) removed after the last administration of inhibitors (day 31), from control mice (vehicle) and from mice treated with the association of AZD6244-BEZ235 or of PLX4720-BEZ235, as described in the legend to Supplementary Figure 5. Insets, higher magnification of a representative area of each panel highlighting the extent of staining for p-ERK and p-AKT in melanoma cells. Original magnification, 20x.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26678033/" target="_blank">26678033</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>